To improve the prognostic scores of patients receiving HMA + VEN, the Beat-AML score added a mutation score based on the presence of IDH2, KRAS, MLL2, and TP53 mutations, redefining AML patients who were earlier categorized as adverse risk based on ELN 2022 in an intermediate (−1 or 0 point) and an adverse risk group (1+ points). The gene discussed is TP53; the disease is acute myeloid leukemia.